CDC study provides first real-world information on vaccine effectiveness in 5- to 11-year-olds — ScienceDaily


Utilizing information from 10 states, a research from the U.S. Facilities for Illness Management and Prevention (CDC) is without doubt one of the first real-world research to point out that two doses of an mRNA vaccine present safety towards COVID-19 related emergency division and pressing care visits amongst kids ages 5 to 11.

The research additionally discovered that two doses of an mRNA vaccine present safety towards COVID-19 related emergency division and pressing care visits in addition to very excessive safety towards hospitalization amongst adolescents aged 12 to 17.

“A optimistic sample, just like what we have now reported in adults is rising,” stated research co-author Shaun Grannis, M.D., M.S., vice chairman for information and analytics at Regenstrief Institute and professor of household drugs at Indiana College College of Drugs. “Prevention of emergency division and pressing care visits exhibits that the vaccines are thwarting reasonable COVID-19 in each kids and adolescents; prevention of hospitalizations in 12- to-17-year-olds signifies vaccine effectiveness towards extra critical illness on this age group, which we hope to additionally see in 5-to-11-year-olds when there may be adequate information.

“We now have compelling proof that vaccines and, for 16- and 17-year-olds, boosters, present necessary safety for each kids and adolescents — data-driven info that oldsters ought to consider when making selections for his or her household,” stated Dr. Grannis.

The research was performed by the CDC’s VISION Community which incorporates, along with the Regenstrief Institute (Indiana), Baylor Scott & White Well being (Texas), Columbia College Irving Medical Middle (New York), HealthPartners (Minnesota and Wisconsin), Intermountain Healthcare (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente Northwest (Oregon and Washington) and College of Colorado (Colorado).

“Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Stopping COVID-19-associated Emergency Division and Pressing Care Encounters and Hospitalizations Amongst Non-Immunocompromised Kids and Adolescents Aged 5-17 Years — VISION Community, Ten States, April 2021-January 2022” is revealed within the CDC’s Morbidity and Mortality Weekly Report.

Regenstrief Institute authors of the research, along with Dr. Grannis, are William F. Fadel, PhD and Brian E. Dixon, PhD, MPA, Regenstrief and IU Richard M. Fairbanks College of Public Well being; Nimish Ramesh Valvi, DrPH, MBBS, a Regenstrief fellow; and Peter J. Embi, M.D., M.S., former Regenstrief president, and a present affiliate scientist.

All authors on this paper are Nicola P. Klein, M.D., Kaiser Permanente Vaccine Examine Middle, Kaiser Permanente Northern California Division of Analysis; Melissa Stockwell, M.D., Division of Little one and Adolescent Well being, Division of Pediatrics, Columbia College Vagelos Faculty of Physicians and Surgeons, Division of Inhabitants and Household Well being, Columbia College Mailman College of Public Well being, New York-Presbyterian Hospital; Maria Demarco, PhD, Westat; Manjusha Gaglani, MBBS, Baylor Scott & White Well being, Texas A&M College Faculty of Drugs; Anupam B. Kharbanda, M.D., Kids’s Minnesota; Stephanie A. Irving, MHS, Middle for Well being Analysis, Kaiser Permanente Northwest; Suchitra Rao, MBBS, College of Drugs, College of Colorado Anschutz Medical Campus; Shaun J. Grannis, M.D., Middle for Biomedical Informatics, Regenstrief Institute, Indiana College College of Drugs; Kristin Dascomb, M.D., Division of Infectious Illnesses and Scientific Epidemiology, Intermountain Healthcare; Kempapura Murthy, MBBS, Baylor Scott & White Well being; Elizabeth A. Rowley, DrPH, Westat; Alexandra F. Dalton, PhD, Facilities for Illness Management and Prevention COVID-19 Response Group; Malini B. DeSilva, M.D., HealthPartners Institute; Brian E. Dixon, PhD, Middle for Biomedical Informatics, Regenstrief Institute, Fairbanks College of Public Well being, Indiana College; Karthik Natarajan, PhD, New York-Presbyterian Hospital, Division of Biomedical Informatics, Columbia College Irving Medical Middle; Edward Stenehjem, M.D., Division of Infectious Illnesses and Scientific Epidemiology, Intermountain Healthcare; Allison L. Naleway, PhD, Middle for Well being Analysis, Kaiser Permanente Northwest; Ned Lewis, MPH, Kaiser Permanente Vaccine Examine Middle, Kaiser Permanente Northern California Division of Analysis; Toan C. Ong, PhD, Kids’s Minnesota; Palak Patel, MBBS, Facilities for Illness Management and Prevention COVID-19 Response Group; Deepika Konatham, Baylor Scott & White Well being; Peter J. Embi, M.D., Indiana College College of Drugs, Regenstrief Institute, Vanderbilt College Medical Middle; Sarah E. Reese, PhD, Westat; Jungmi Han, Division of Biomedical Informatics, Columbia College Irving Medical Middle; Nancy Grisel, MPP, Division of Infectious Illnesses and Scientific Epidemiology, Intermountain Healthcare; Kristin Goddard, MPH, Kaiser Permanente Vaccine Examine Middle, Kaiser Permanente Northern California Division of Analysis; Michelle A. Barron, M.D., College of Drugs, College of Colorado Anschutz Medical Campus; Monica Dickerson, Facilities for Illness Management and Prevention COVID-19 Response Group; I-Chia Liao, MPH, Baylor Scott & White Well being; William F. Fadel, PhD, Middle for Biomedical Informatics, Regenstrief Institute, Fairbanks College of Public Well being, Indiana College; Duck-Hye Yang, PhD, Westat; Julie Arndorfer, MPH, Division of Infectious Illnesses and Scientific Epidemiology, Intermountain Healthcare; Bruce Fireman, Kaiser Permanente Vaccine Examine Middle, Kaiser Permanente Northern California Division of Analysis; Eric P. Griggs, MPH, Facilities for Illness Management and Prevention COVID-19 Response Group; Nimish R. Valvi, DrPH, Middle for Biomedical Informatics, Regenstrief Institute; Carly Hallowell, MPH, Westat; Ousseny Zerbo, PhD, Kaiser Permanente Vaccine Examine Middle, Kaiser Permanente Northern California Division of Analysis; Sue Reynolds, PhD, Facilities for Illness Management and Prevention COVID-19 Response Group; Jill Ferdinands, PhD, Facilities for Illness Management and Prevention COVID-19 Response Group; Mehiret H. Wondimu, MPH, Facilities for Illness Management and Prevention COVID-19 Response Group; Jeremiah Williams, MPH, Facilities for Illness Management and Prevention COVID-19 Response Group; Catherine H. Bozio, PhD, Facilities for Illness Management and Prevention COVID-19 Response Group; Ruth Hyperlink-Gelles, PhD, Facilities for Illness Management and Prevention COVID-19 Response Group; Eduardo Azziz-Baumgartner, M.D., Facilities for Illness Management and Prevention COVID-19 Response Group; Stephanie J. Schrag, DPhil, Facilities for Illness Management and Prevention COVID-19 Response Group; Mark G. Thompson, PhD, Facilities for Illness Management and Prevention COVID-19 Response Group; Jennifer R. Verani, M.D., Facilities for Illness Management and Prevention COVID-19 Response Group.

Leave a Reply